

Original Article

*Joint first authorship.

Cite this article: Grotmol KS, Lie HC, Loge JH, Aass N, Haugen DF, Stone PC, Kaasa S, Hjermstad MJ on behalf of the European Palliative Care Research Collaborative (EPCRC) (2019). Patients with advanced cancer and depression report a significantly higher symptom burden than non-depressed patients. *Palliative and Supportive Care* **17**, 143–149. <https://doi.org/10.1017/S1478951517001183>

Received: 25 October 2017

Revised: 22 November 2017

Accepted: 26 November 2017

Key words:

Advanced cancer; depression; prognosis; symptoms

Author for correspondence:

Kjersti Støen Grotmol, Regional Advisory Unit for Palliative Care, Department of Oncology, Oslo University Hospital, Postboks 4956 Nydalen, 0424 Oslo, Norway. E-mail: k.s.grotmol@medisin.uio.no

Patients with advanced cancer and depression report a significantly higher symptom burden than non-depressed patients

Kjersti Støen Grotmol, PH.D.^{1,*}, Hanne C. Lie, PH.D.^{2,3,4,*}, Jon Håvard Loge, PH.D.^{1,3,5}, Nina Aass, PH.D.^{6,7}, Dagny Faksvåg Haugen, PH.D.^{8,9}, Patrick C. Stone, M.D.¹⁰, Stein Kaasa, PH.D.^{5,6,7} and Marianne Jensen Hjermstad, PH.D.^{1,5} on behalf of the European Palliative Care Research Collaborative (EPCRC)

¹Regional Advisory Unit for Palliative Care, Department of Oncology, Oslo University Hospital; ²Department of Paediatric Medicine, Oslo University Hospital, Oslo, Norway; ³Department of Behavioural Sciences in Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; ⁴National Advisory Unit on Late Effects after Cancer Treatment, Oslo University Hospital, Oslo, Norway; ⁵European Palliative Care Research Centre (PRC), Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology and St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway; ⁶Faculty of Medicine, University of Oslo, Oslo, Norway; ⁷Department of Oncology, Oslo University Hospital, Oslo, Norway; ⁸Regional Centre of Excellence for Palliative Care, Western Norway, Haukeland University Hospital, Bergen, Norway; ⁹Department of Clinical Medicine K1, University of Bergen, Bergen, Norway and ¹⁰Marie Curie Palliative Care Research Department, University College London, UK

Abstract

Objective. Clinical observations indicate that patients with advanced cancer and depression report higher symptom burden than nondepressed patients. This is rarely examined empirically. Study aim was to investigate the association between self-reported depression disorder (DD) and symptoms in patients with advanced cancer controlled for prognostic factors.

Method. The sample included 935 patients, mean age 62, 52% males, from an international multicentre observational study (European Palliative Care Research Collaborative – Computerised Symptom Assessment and Classification of Pain, Depression and Physical Function). DD was assessed by the Patient Health Questionnaire-9 and scored with Diagnostic and Statistical Manual of Mental Disorder-5 algorithm for major depressive disorder, excluding somatic symptoms. Symptom burden was assessed by summing scores on somatic Edmonton Symptom Assessment Scale (ESAS) symptoms, excluding depression, anxiety, and well-being. Item-by-item scores and symptom burden of those with and without DD were compared using nonparametric Mann-Whitney *U* tests. The relative importance of sociodemographic, medical, and prognostic factors and DD in predicting symptom burden was assessed by hierarchical, multiple regression analyses.

Result. Patients with DD reported significantly higher scores on ESAS items and a twofold higher symptom burden compared with those without. Factors associated with higher symptom burden were as follows. Diagnosis: lung ($\beta = 0.15$, $p < 0.001$) or breast cancer ($\beta = 0.08$, $p < 0.05$); poorer prognosis: high C-reactive protein ($\beta = 0.08$, $p < 0.05$), lower Karnofsky Performance Status ($\beta = -0.14$, $p < 0.001$), and greater weight loss ($\beta = -0.15$, $p < 0.001$); taking opioids ($\beta = 0.11$, $p < 0.01$); and having DD ($\beta = 0.23$, $p < 0.001$). The full model explained 18% of the variance in symptom burden. DD explained 4.4% over and above that explained by all the other variables.

Significance of results. Depression in patients with advanced cancer is associated with higher symptom burden. These results encourage improved routines for identifying and treating those suffering from depression.

Introduction

The main goal of supportive and palliative care for patients living with or affected by cancer is to improve their quality of life (WHO, 2002), which implies a clear obligation to ensure optimal symptom management (Hui, 2014). Patients with advanced cancer generally report a range of somatic symptoms that, for most patients, increase in intensity with disease progression (Maltoni, 2005). The negative impact of these symptoms on patients' functional status and quality of life is well known (Ferreira et al., 2008), yet there is evidence that many symptoms are left unrecognized (Greco et al., 2014).

Depression in patients with advanced cancer is relatively common, with average prevalence rate estimates around 15% using structured clinical interviews or patient-reported measures that include the diagnostic criteria of a depressive disorder (Lie et al., 2015; Mitchell et al., 2011). Nevertheless, depression in patients with advanced cancer is often not detected in

the clinic, hampering adequate treatment (Kadan-Lottick et al., 2005; Sanjida et al., 2015). Depression is associated with reduced functional status, lower treatment compliance, prolonged hospitalizations, and desire for hastened death (Brown et al., 2010; Lloyd-Williams et al., 2009). In clinical practice, it is often assumed that depression affects both the presence and intensity of somatic symptoms (Ciaramella & Poli, 2001), and that patients who are depressed may have physical symptoms that are difficult to manage (Chochinov et al., 1997).

A symptom is defined as any subjective evidence of disease or unusual state, and accordingly can only be perceived by the individual affected (Dodd et al., 2001). Recent research from non-cancer medical populations suggests that an interaction between medical and psychological factors contributes to the experience and reporting of somatic symptoms (Kroenke & Rosmalen, 2006). In line with this, numerous studies also from non-cancer populations consistently report associations between depression and increased levels of somatic symptoms (Katon et al., 2007), albeit sparsely studied in cancer settings (Novy et al., 2005). Most studies in cancer settings to date have explored this in mixed populations, focusing on specific somatic symptoms, primarily pain and fatigue (Brown & Kroenke, 2009; O'Connor et al., 2012). Indeed, depressive symptoms are found to co-occur with pain and fatigue among cancer patients with mixed diagnoses (Brown & Kroenke, 2009; Zaza & Baine, 2002). It could be that psychological factors play a role in the experience and reporting of a range of somatic symptoms, not only pain and fatigue (Kroenke & Rosmalen, 2006). Besides, the relationship between depression and somatic symptoms may vary through the disease trajectory. A handful of small-sized studies on patients with advanced cancer have explored the relationship between depression and a number of symptoms. The findings are equivocal because studies both support (Fitzgerald et al., 2013), reject (Teunissen et al., 2007), or report mixed findings (Delgado-Guay et al., 2009) regarding such a relationship. Despite consistent reports that poor prognosis is related to both increased somatic symptom burden (Maltoni, 2005) and depression (Lo et al., 2010), the potential effect of disease-related factors on symptom burden was considered in only one of these studies (Fitzgerald et al., 2013). Finally, assessment of depression in cancer populations is challenging, primarily because of the overlap of depressive symptoms and cancer- and treatment-related symptoms and of functional impairments and depression (Wasteson et al., 2009). Studies of depression in patients with advanced cancer have used a range of different assessment instruments (Wasteson et al., 2009), and few differentiate between depressive symptoms and an established *depressive disorder*, as defined by diagnostic criteria and recommended by American Society of Clinical Oncology (Andersen et al., 2014). Given these methodological issues, the inconsistent results of the few studies to date are perhaps not surprising (Fitzgerald et al., 2013; Lloyd Williams et al., 2004; Zaza & Baine, 2002). Hence, it remains unclear whether depression is associated with, and thus may contribute to, increased somatic symptom burden among patients with advanced cancer *irrespective of* prognostic factors.

Therefore, the aim of the present study was to compare the intensity of somatic symptoms as reported by patients meeting the criteria for depressive disorder with that of patients not meeting these criteria. Based on clinical experience, we hypothesized that patients with depression report a higher symptom burden than those without. Results in support of this hypothesis serve as a strong incentive to increase the focus on detecting and treating

comorbid depression in the clinic also as a means to improve symptom management. Moreover, we wanted to explore the relative contribution of demographic, medical, and prognostic factors; medication use; and depression to increased symptom burden.

Methods

Study design and patients

Data were collected through a large international cross-sectional study from the EU-funded European Palliative Care Research Collaborative project (Kaasa et al., 2008). From 2008 to 2009, 1,051 patients with advanced cancer were recruited from 17 centers in eight countries, including in- and out-patient units, hospices/inpatient palliative care beds, and general oncology and medical wards. Inclusion criteria were: incurable metastatic or locally advanced cancers and age 18 years or above (Hjermstad, 2012). Of the 1,051 patients, 969 completed the symptom (Edmonton Symptom Assessment Scale [ESAS]) and depression (Patient Health Questionnaire-9 [PHQ-9]) assessments. Of these, patients with a likely moderate or severe cognitive impairment (sum-score <18, Mini-Mental State Exam (MMSE), $n = 12$) (Folstein et al., 1975) or those with missing MMSE-scores ($n = 22$) were excluded, leaving a final sample of $n = 935$ in this paper.

Study measurements

Sociodemographic and medical data were collected by healthcare providers, whereas participants completed a range of patient-reported instruments directly on touch-sensitive tablet computers (Brændengen et al., 2012).

Medical status

Medical status included the primary cancer diagnosis and current disease status: locoregionally advanced or metastatic (Table 1).

Prognostic factors

Medical information was retrieved from patient records and healthcare provider registrations, including Karnofsky Performance Status scores (Karnofsky, 1948); dichotomous registration of comorbidities (heart disease, arthritis, chronic obstructive pulmonary disease, renal disease, liver disease, and "other") and C-reactive protein (CRP) values if obtained within 3 days of study inclusion. High CRP was defined as CRP >10 mg/L. Weight change past 6 months was calculated as self-reported weight in kilograms 6 months ago minus current self-reported weight.

Medication use

Current use of opioids and antidepressants not as adjuvant for pain was dichotomized (use vs. not use).

Depression

Depression was assessed using the PHQ-9, a self-report questionnaire commonly used in medically ill samples, including patients with cancer (Johns et al., 2013; Lie et al., 2015). The PHQ-9 items correspond to the Diagnostic and Statistical Manual of Mental Disorder-5 diagnostic criteria for major depressive disorder (MDD) and assess the frequency at which the corresponding symptoms have been bothersome during the past 2 weeks: 0 = not at all, 1 = several days, 2 = more than half the days, and 3 = nearly every day. To avoid artificially inflating potential relationships between depression and symptom burden in this paper, we used an

Table 1. Characteristics of the 935 patients included in the analysis

Continuous variables	Mean	SD	Range
Age	62.1	12.39	18–89
MMSE	28.0	2.39	18–30
KPS	71.2	16.12	20–100
Total number comorbidities ¹	0.7	0.87	0–6
ESAS sum-score somatic symptoms ²	15.5	9.78	0–48
Categorical variables	<i>n</i> ³		%
Gender			
Female	452		48
Male	483		52
Education			
<10 years	319		34
10–12 years	331		35
>12 years	285		31
Marital status ⁴			
Spouse	613		66
No spouse	322		34
Nationality			
Norwegian	476		51
Not Norwegian	459		49
CRP ⁵			
Normal	303		45
High >10	367		55
Setting			
In-patient	527		56
Out-patient	408		44
Site of primary cancer			
Gastrointestinal tract	249		27
Lungs	154		16
Breast	164		18
Prostate and male genital organs	100		11
Other ⁶	267		29
Current disease status			
Metastatic ⁷	794		85
Locoregionally advanced	141		15
Use of opioids			
Yes	529		57
No	406		43
Use of antidepressants ⁸			
Yes	124		13
No	881		87
Depression			

(Continued)

Table 1. (Continued.)

Continuous variables	Mean	SD	Range
Yes	134		14
No	801		86

CRP, C-reactive protein; ESAS, Edmonton Symptom Assessment Scale; KPS, Karnofsky Performance Status score, where 100 = normal functioning and 0 = dead; MMSE = Mini Mental State Examination; SD, standard deviation.

¹Comorbidities: heart disease, arthritis, chronic obstructive pulmonary disease, renal and liver disease, and other.

²Sum-score of the six somatic symptoms on the ESAS, excluding depression, anxiety, and feeling of well-being. Possible range: 0–60, where a higher score indicates higher symptom burden.

³Number of patients for each variable may not add up to 935 because of missing cases.

⁴Spouse denotes cohabiting with a partner, married or unmarried.

⁵CRP: normal = CRP ≤10 mg/L, high = CRP >10 mg/L.

⁶Other cancers include: urinary tract (5.6%), skin including malignant melanomas (4.0%), leukemia/lymphoma (4.6%), secondary/ill-defined malignant tumors (2.6%), malignant connective/soft tissue tumors (3.3%), head and neck (3.0%), gynecological (2.6%), tumors of the central nervous system (1.5%), malignant endocrine tumors (0.7%), multiple primary cancers (0.4%).

⁷Metastatic disease includes one or more metastases in the following locations; bone, brain, liver, lungs, lymph nodes, or other.

⁸Antidepressants not taken as an adjuvant for pain.

exclusive scoring method based on the Diagnostic and Statistical Manual of Mental Disorder-5 scoring algorithm (Lie et al., 2015). This scoring method excludes four somatic symptoms likely to reflect the cancer disease (sleep problems, fatigue, change of weight or appetite, and psychomotor retardation/agitation) and requires three of the remaining five criteria to be present, including anhedonia or depressed mood (Zimmermann et al., 2011). Although the PHQ-9 is not a diagnostic tool, patients meeting the criteria for exclusive DD were categorized as depressed in this study.

Symptom burden

Symptom burden was measured using the original Edmonton Symptom Assessment Scale (ESAS) (Bruera, 1991) scored on 11-point numerical rating scales with 0 as “no symptom at all” and 10 as “worst possible symptom.” In the multivariate model, the sum-score of the six somatic ESAS symptoms was calculated, excluding depression, anxiety, and feeling of well-being due to content overlap with depression. A higher sum-score (range 0–60) indicates higher symptom burden.

Statistical methods

Variables to be included in the multivariate models were determined using bivariate regression models with statistical significance set at $p < 0.10$. Candidate variables were: medical status variables; prognostic factors; medication use; and DD. Demographic variables were controlled for in the multivariate models. Multivariate, hierarchical regression was used to explore the relationships between the above-mentioned variables and the sum-score of the somatic ESAS symptoms. This method allowed us to estimate the unique variance in the ESAS sum-score accounted for by the groups of variables. P values < 0.05 were considered statistically significant. Statistical analyses were done using IBM-SPSS 22 (Armonk, NY: IBM Corp.).

Ethical considerations

The study was performed according to the Helsinki declaration. Ethical approval was obtained at each site before study start. All participants gave written informed consent.

Results

Sample characteristics

Characteristics of the sample are provided in Table 1. In brief, the sample consisted of 48% female patients and the mean age was 62.1 years. The most common site of the primary cancer was the gastrointestinal tract (27%) and 85% had metastatic disease. Of the 935 patients, 801 (85.7%) were not depressed and 134 (14.3%) scored at or above the cutoff for being depressed.) Anti-depressants not as an adjuvant to pain medication were used by 92 (11.5%) patients in the non-depressed group and by 32 (23.9%) patients in the depressed group.

Group comparisons of individual ESAS symptoms

For the purpose of exploring symptom load in terms of individual somatic ESAS symptoms for those depressed or not, we divided

the sample into four groups: (1) not depressed and not taking ADs ($n = 709$), (2) not depressed and taking ADs ($n = 92$), (3) depressed and not taking ADs ($n = 102$), and (4) depressed and taking ADs ($n = 32$). Non-parametric Mann-Whitney U tests showed no significant differences between the two non-depressed groups not using or using ADs, or between the two depressed groups not using or using ADs. For the purpose of further analyses we therefore collapsed the four groups into two: not-depressed ($n = 801$) and depressed ($n = 144$). The depressed patients scored significantly higher on all somatic ESAS symptoms compared to the non-depressed ($p < 0.001$ for all).

Determinants of ESAS sum-score

The univariate and multivariate models predicting sum-score of the ESAS somatic symptoms are presented in Table 2. The following variables were significantly associated with a higher sum-score

Table 2. Univariate and hierarchical multivariate regression models predicting the sum-scores of the ESAS somatic symptoms

Model steps	Univariate	Multivariate				
		1	2	3	4	5
Demographics						
Gender ¹	0.01	-0.02	-0.03	-0.02	-0.03	-0.04
Age ²	-0.01	-0.05	-0.05	-0.05	-0.05	-0.04
Education						
High school	-0.08 [#]	-0.06	-0.05	-0.04	-0.04	-0.04
University	-0.08 [#]	-0.03	-0.01	0.02	0.02	0.03
Marital status ³	0.02					
Medical status						
Diagnosis ⁴						
Breast cancer	0.10**		0.06	0.10*	0.09*	0.09*
Lung cancers	0.12**		0.16**	0.13**	0.14**	0.15***
Gastrointestinal cancers	0.03		0.06	0.07	0.08	0.08
Male genital cancers	-0.02		0.03	0.02	0.01	0.02
Total comorbidities	0.04					
Prognostic factors ⁵						
CRP (high)	0.17***			0.12**	0.10*	0.08*
KPS	-0.30***			-0.22***	-0.18***	-0.14***
Weight change (last 6 months)	-0.21***			-0.19***	-0.18***	-0.15***
Medication use						
ADs	0.06 [#]				0.01	0.01
Opioids	0.27***				0.12**	0.11**
Depression (DD) ⁶	0.30***					0.23***
R^2_{adj}		0.002	0.010*	0.124***	0.134**	0.180***

Univariate predictors with $p < 0.10$ were included in the multivariate regression model. Standardized beta values are shown.

AD, antidepressant; CRP, C-reactive protein; DD, depression disorder; ESAS, Edmonton Symptom Assessment Scale; KPS, Karnofsky Performance Status.

In step 5: $N = 623$. Significance levels indicated by: [#] < 0.10 , * < 0.05 , ** < 0.01 , *** < 0.001 .

¹Male (vs. female).

²Age categorized in decades: 18–27, 28–37, 38–47, 48–57, 58–67, 68–77, 78–87, 88–100.

³Married/de facto vs. not married/divorced/single.

⁴Diagnoses: Reference category = all other diagnoses.

⁵CRP: reference category = normal = CRP ≤ 10 mg/L, KPS, weight change: (self-reported weight 6 months ago) – (current self-reported weight).

⁶Reference category = no DD. DD, meeting the criteria for a depression disorder using the Diagnostic and Statistical Manual of Mental Disorder-5 scoring algorithm excluding the somatic symptoms.

in the univariate analysis; diagnosed with breast cancer ($\beta = 0.10$, $p = 0.006$) or lung cancer ($\beta = 0.12$, $p = 0.002$), prognostic factors including high CRP ($\beta = 0.17$, $p < 0.001$), lower Karnofsky performance score ($\beta = -0.30$, $p < 0.001$) and greater self-reported weight loss the past 6 months ($\beta = -0.21$, $p < 0.001$); taking opioids ($\beta = 0.27$, $p < 0.001$) and meeting the criteria for MDD ($\beta = -0.30$, $p < 0.001$). The multivariate model accounted for 18% of the variance in the ESAS sum scores. Of this, step 1, the demographic variables accounted for 0.2%; step 2, medical status 9.8%; step 3, prognostic factors 2.4%; step 4, medication use 1%; and step 5, DD 4.6% of the variance over and above the variance accounted for by the previous steps in the model. In the fifth and final step of the model, higher symptom burden was associated most strongly with depression ($\beta = -0.23$, $p < 0.001$) after controlling for the effects of all other variables, followed by greater weight loss over the past 6 months ($\beta = -0.15$, $p < 0.001$), being diagnosed with lung cancer ($\beta = 0.15$, $p < 0.001$), lower performance status ($\beta = -0.14$, $p < 0.001$), and taking opioids ($\beta = -0.11$, $p < 0.001$).

Discussion

To the best of our knowledge, the present study is the first to examine the relationship between depression according to diagnostic criteria, and self-reported somatic symptom burden in a large sample of patients with advanced cancer while also considering disease-related factors. In line with our main hypothesis, being categorized as depressed was significantly associated with higher somatic symptom burden.

It is known that depressed individuals' negative and pessimistic way of thinking promotes a negative view of their health and results in heightened awareness of unpleasant experiences (Howren & Suls, 2011). Although these mechanisms primarily have been suggested to play a role in illnesses characterized by medically unexplained symptoms (Kroenke & Rosmalen, 2006), recent research has proposed that disease specific symptoms (e.g., dyspnea in pulmonary disorders or chest pain in cardiac disease) may be partly accounted for by comorbid depression, which adds to the physical severity of the underlying medical disorder (Katon et al., 2007). Similarly, it is likely that medical and psychological factors interplay in the experience and reporting of physical symptoms of cancer disease and treatment as well. Our finding that depression is independently associated with a range of somatic symptoms, rather than just a few specific ones, is consistent with this assertion. Longitudinal studies, however, are needed to clarify the potential reciprocity in the interplay between medical and psychological factors. Somatic disease may indeed have an etiological role in the genesis of depression, supported by studies that have identified physical distress as a risk factor for the development of depression (Lo et al., 2010).

The emotional, interpersonal, and health economical costs of depression are considerable (Brown et al., 2010; Lloyd Williams et al., 2009). Even though pharmacological and psychosocial interventions are documented to effectively reduce depression in patients with advanced cancer (Rayner et al., 2011), nurses and doctors frequently fail to detect it. Many healthcare personnel believe they do not have the skills to assess and recognize depression (McCabe et al., 2012). Complicating this further is the common misconception among patients and healthcare personnel that the other party should initiate discussions about psychological issues (Detmar, 2000). Consequently, a considerable undertreatment in this patient group has been documented (Kadan-Lottick et al., 2005; Sanjida et al., 2016).

One limitation of the present study is its cross-sectional design, which prohibits us from drawing conclusions on directionality. Thus, answering the question of possible bidirectional effects between depression and symptoms necessitates longitudinal investigations. In addition, the use of self-report to measure both depression and symptom severity may have caused conflated associations between variables (i.e., common method variance). We believe, however, that this problem was reduced by excluding the somatic symptoms from our depression measure and including objectively assessed indicators of prognosis such as Karnofsky Performance Status and CRP measures. We lack information about patients who were not invited or declined participation; however, the most severely affected patients are not likely to have been included because of gate-keeping by the recruiting healthcare workers. Also of note is the use of self-report to assess depression rather than the gold standard (i.e., a structured psychiatric interview). Nevertheless, the PHQ-9 corresponds to the criteria used in the Structured Clinical Interview for DSM-MDD interview (Spitzer et al., 1999), hence the main difference is the mode of administration, not the content. Indeed, the PHQ-9 is the screening tool recommended for assessment of depression by American Society of Clinical Oncology (Andersen et al., 2014).

The main strength of this study is the large, international sample of patients with advanced cancer characterized on a broad range of symptoms, functioning, and medical status. Further, we not only controlled for disease- and treatment-related factors, but also for objective measures of prognosis.

Conclusions and implications

In this large and well-characterized sample of patients with advanced cancer, depression was associated with an increased somatic symptom burden when controlled for disease, treatment status, and prognosis. Our findings are in line with the suggestion that psychological as well as organic factors affect the experience of somatic symptoms in patients with advanced cancer. Future research should investigate prospectively whether improvement of depression, assessed by validated means, results in reduction of somatic symptom burden. When clinicians are assessing and managing symptoms among patients for whom cure is no longer feasible and the aim of care is best possible quality of life, they should consider the potential for a comorbid depression. Given that depression in patients can be treated effectively even in the last few weeks of life (Walker et al., 2014), patients presenting with a high intensity across a wide array of symptoms should make clinicians especially attentive to such comorbidity.

Conclusively, the results of the present study clearly support the argument in the Institute of Medicine's report, namely that cancer care can be improved by attending not only to the patient's biomedical needs, but to all aspects of the patient's situation (Young, 2007).

Acknowledgments. The European Palliative Care Research Collaborative was funded by the European Commission's Sixth Framework Programme (contract no LSHC-CT-2006-037777) with the overall aim to improve treatment of pain, depression and fatigue through translation research. Core scientific group/work package leaders: Stein Kaasa (project coordinator), Frank Skorpen, Marianne Jensen Hjermsstad, and Jon Håvard Loge, Norwegian University of Science and Technology (NTNU); Geoffrey Hanks, University of Bristol; Augusto Caraceni and Franco De Conno, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Irene Higginson, King's College London; Florian Strasser, Cantonal Hospital St. Gallen; Lukas Radbruch, RWTH Aachen University; Kenneth Fearon, University of Edinburgh;

Hellmut Samonigg, Medical University of Graz; Ketil Bø, Trollhetta AS, Norway; Irene Rech-Weichselbraun, Bender MedSystems GmbH, Austria; Odd Erik Gundersen, Verdande Technology AS, Norway. Scientific advisory group: Neil Aaronson, The Netherlands Cancer Institute; Vickie Baracos and Robin Fainsinger, University of Alberta; Patrick C. Stone, St. George's University of London; and Mari Lloyd-Williams, University of Liverpool. Project management: Stein Kaasa, Ola Dale, and Dagny F. Haugen, NTNU, Norway.

Conflicts of interest. None.

Role of funding source. The study was supported by grant LSHC-CT-2006-037777 by the European Commission's Sixth Framework Programme (EPCRC) and a grant by the Norwegian Cancer society, project no. 171874 - PR-2009-0319. The University of Oslo provided material support for the current report. The sponsors provided financial support for the study only. They had no role in the design and conduct of the study: the collection, management, analysis, and interpretations of the data; or in the preparation, review or approval of the manuscript.

References

- Andersen B., DeRubeis RJ, Berman BS, *et al.* (2014) Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. *Journal of Clinical Oncology* **32**, 1605–1619.
- Brown LF and Kroenke K (2009) Cancer-related fatigue and its associations with depression and anxiety: a systematic review. *Psychosomatics* **50**, 440–447.
- Brown LK, Theobald DE, Wu J, and Tu W (2010) The association of depression and anxiety with health-related quality of life in cancer patients with depression and/or pain. *Psychooncology* **19**, 7314–7341.
- Bruera E (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. *Journal of Palliative Care* **7**, 6–9.
- Brændengen M, Tveit K, Hjerbstad M, *et al.* (2012). Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long-term results from a phase III study. *European Journal of Cancer* **48**, 813–819.
- Ciarrella A and Poli P (2001) Assessment of depression among cancer patients: The role of pain, cancer type and treatment. *Psychooncology* **10**, 156–165.
- Chochinov HM., Wilson KG, Enns M, Lander S (1997) 'Are you depressed?' Screening for depression in the terminally ill. *The American Journal of Psychiatry* **154**, 674–676.
- Delgado-Guay M, Parsons H, Li Z, *et al.* (2009) Symptom distress in advanced cancer patients with anxiety and depression in the palliative care setting. *Supportive Care in Cancer* **17**, 573–579.
- Detmar SB (2000) How are you feeling? Who wants to know? Patients' and oncologists' preferences for discussing health-related quality-of-life issues. *Journal of Clinical Oncology* **18**, 3295–3301.
- Dodd M, Janson S, Facione N, *et al.* (2001) Advancing the science of symptom management. *Journal of Advanced Nursing* **33**, 668–676.
- Ferreira KASL, Kimura M, Teixeira M, *et al.* (2008) Impact of cancer-related symptom synergisms on health-related quality of life and performance status. *Journal of Pain and Symptom Management* **35**, 604–616.
- Fitzgerald P, Li M, Gagliese L, *et al.* (2013) The relationship between depression and physical symptom burden in advanced cancer. *BMJ Supportive Palliative Care* **5**, 1–8.
- Folstein MF, Folstein SE, and McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *Journal of Psychiatry Research* **12**, 189–198.
- Greco MT, Roberto A, Corli O, *et al.* (2014) Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. *Journal of Clinical Oncology* **32**, 4149–4154.
- Hjerbstad M, Lie H, Caraceni A, *et al.* (2012) Computer-based symptom assessment is feasible in patients with advanced cancer: results from an international multicenter study, the EPCRC-CSA. *Journal of Pain and Symptom Management* **44**, 639–654.
- Hui D (2014) Definition of supportive care: does the semantic matter? *Current Opinion in Oncology* **26**, 372–379.
- Howren MB and Suls J (2011) The symptom perception hypothesis revisited: depression and anxiety play different roles in concurrent and retrospective physical symptom reporting. *Journal of Personality and Social Psychology* **100**, 182–195.
- Johns SA, Kroenke K, Krebs EE, *et al.* (2013) Longitudinal comparison of three depression measures in adult cancer patients. *Journal of Pain and Symptom Management* **45**, 71–82.
- Kaasa S, Loge JH, Fayers P, *et al.* (2008). Symptom assessment in palliative care: a need for international collaboration. *Journal of Clinical Oncology* **26**, 3867–3873.
- Kadan-Lottick NS, Vanderwerker LC, Block SD, *et al.* (2005) Psychiatric disorders and mental health service use in patients with advanced cancer: a report from the coping with cancer study. *Cancer* **104**, 2872–2881.
- Karnofsky D (1948) The use of nitrogen mustards in the palliative treatment of carcinoma with particular reference to bronchogenic carcinoma. *Cancer* **1**, 634–656.
- Katon W, Lin EHB, Kroenke K (2007) The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. *General Hospital Psychiatry* **29**, 147–155.
- Kroenke K and Rosmalen JGM (2006) Symptoms, syndromes, and the value of psychiatric diagnostics in patients who have functional somatic disorders. *The Medical Clinics of North America* **90**, 603–626.
- Lie HC, Hjerbstad MJ, Fayers P, *et al.* (2015) Depression in advanced cancer – assessment challenges and associations with disease load. *Journal of Affective Disorders* **173**, 176–184.
- Lloyd Williams M, Dennis M, and Taylor F (2004) A prospective study to determine the association between physical symptoms and depression in patients with advanced cancer. *Palliative Medicine* **18**, 558–563.
- Lloyd Williams M, Shiels C, Taylor F, and Dennis M (2009) Depression — an independent predictor of early death in patients with advanced cancer. *Journal of Affective Disorders* **113**, 127–132.
- Lo C, Zimmermann C, Rydall A, *et al.* (2010). Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer. *Journal of Clinical Oncology* **28**, 3084–3089.
- Maltoni M (2005) Prognostic factors in advanced cancer patients: evidence-based clinical recommendations – a study by the Steering Committee of the European Association for Palliative Care. *Journal of Clinical Oncology* **23**, 6240–6248.
- McCabe MP, Mellor D, Davison TE, *et al.* (2012) Detecting and managing depressed patients: palliative care nurses' self-efficacy and perceived barriers to care. *Journal of Palliative Medicine* **15**, 463–467.
- Mitchell AJ, Chan M, Bhatti H, *et al.* (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. *Lancet Oncology* **12**, 160–174.
- Novy D, Berry MP, Palmer JL, *et al.* (2005) Somatic symptoms in patients with chronic non-cancer-related and cancer-related pain. *Journal of Pain and Symptom Management* **29**, 603–612.
- O'Connor M, Weir J, Butcher I, *et al.* (2012) Pain in patients attending a specialist cancer service: prevalence and association with emotional distress. *Journal of Pain and Symptom Management* **43**, 29–38.
- Rayner L, Price A, Hotopf M, Higginson IJ (2011) The development of evidence-based European guidelines on the management of depression in palliative cancer care. *European Journal of Cancer* **47**, 702–713.
- Sanjida S, Janda M, Kissane D, *et al.* (2016) A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients. *Psychooncology* **25**, 1002–1016.
- Spitzer RL, Kroenke K, and Williams JB (1999) Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. *Journal of American Medical Association* **282**, 1737–1744.
- Teunissen SCCM, de Graeff A, Voest EE, de Haes JCJM (2007) Are anxiety and depressed mood related to physical symptom burden? A study in hospitalized advanced cancer patients. *Palliative Medicine* **21**, 341–346.
- Walker J, Hansen CH, Martin P, *et al.* (2014). Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT

- Oncology-3): a multicentre randomised controlled trial in patients with lung cancer. *Lancet Oncology* **15**, 1168–1176.
- Wasteson E, Brenne E, Higginson IJ, et al.** (2009) Depression assessment and classification in palliative cancer patients: a systematic literature review. *Palliative Medicine* **23**, 739–753.
- WHO (World Health Organization)** (2002) Definition of palliative care. <http://www.who.int/cancer/palliative/definition/en>. Accessed 19 Aug 2017.
- Young P** (2007) Caring for the whole patient: the Institute of Medicine proposes a new standard of care. *Community Oncology* **4**, 748–751.
- Zaza C and Baine N** (2002) Cancer pain and psychosocial factors. *Journal of Pain and Symptom Management* **24**, 526–542.
- Zimmerman M, Emmert-Aronson BO, and Brown TA** (2011) Concordance between a simpler definition of major depressive disorder and Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition: an independent replication in an outpatient sample. *Comprehensive Psychiatry* **52**, 261–264.